

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3696472/publications.pdf>

Version: 2024-02-01

69
papers

5,661
citations

117453

34
h-index

95083

68
g-index

69
all docs

69
docs citations

69
times ranked

7596
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 6212-6222.	3.2	1,012
2	STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. <i>Molecular Cancer</i> , 2017, 16, 136.	7.9	434
3	Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. <i>Lancet Oncology</i> , The, 2012, 13, 817-826.	5.1	337
4	Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. <i>Hepatology</i> , 2013, 57, 1458-1468.	3.6	331
5	Targeted therapy for hepatocellular carcinoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 146.	7.1	320
6	High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. <i>Gut</i> , 2010, 59, 953-962.	6.1	238
7	Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1151-1173.	1.2	160
8	Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1155-1163.	1.2	154
9	CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110 β and predicts poor prognosis. <i>Journal of Hematology and Oncology</i> , 2019, 12, 37.	6.9	150
10	Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection. <i>Clinical Cancer Research</i> , 2008, 14, 3850-3859.	3.2	143
11	A Positive Feedback Loop Between Cancer Stem-Like Cells and Tumor-Associated Neutrophils Controls Hepatocellular Carcinoma Progression. <i>Hepatology</i> , 2019, 70, 1214-1230.	3.6	140
12	CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery. <i>Clinical Cancer Research</i> , 2009, 15, 5518-5527.	3.2	122
13	Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 547-559.	3.2	112
14	MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. <i>Carcinogenesis</i> , 2013, 34, 2071-2079.	1.3	109
15	Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 2203-2213.	3.2	102
16	Clinical Significance of <i>EpCAM</i> mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR-Based Platform. <i>Clinical Cancer Research</i> , 2014, 20, 4794-4805.	3.2	99
17	A novel, liver-specific long noncoding RNA LINC01093 suppresses HCC progression by interaction with IGF2BP1 to facilitate decay of GLI1 mRNA. <i>Cancer Letters</i> , 2019, 450, 98-109.	3.2	94
18	Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 4091.	5.8	90

#	ARTICLE	IF	CITATIONS
19	Up-regulation of KrÄ¼ppel-Like Factor 8 Promotes Tumor Invasion and Indicates Poor Prognosis for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2010, 139, 2146-2157.e12.	0.6	88
20	Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 293-301.	1.8	79
21	Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target. <i>BMC Cancer</i> , 2019, 19, 760.	1.1	78
22	Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/ E2F transcription factor 1-dependent apoptotic pathway. <i>Hepatology</i> , 2013, 57, 1088-1097.	3.6	74
23	High expression of Dickkopfâ€related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery. <i>Cancer</i> , 2013, 119, 993-1003.	2.0	73
24	Osteopontin Combined with CD44, a Novel Prognostic Biomarker for Patients with Hepatocellular Carcinoma Undergoing Curative Resection. <i>Oncologist</i> , 2008, 13, 1155-1165.	1.9	69
25	Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. <i>Cell Death and Disease</i> , 2020, 11, 573.	2.7	65
26	Dynamic change of the systemic immune inflammation index predicts the prognosis of patients with hepatocellular carcinoma after curative resection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1963-1969.	1.4	61
27	A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2015, 468, 525-532.	1.0	59
28	Circulating CD14⁺HLAâ€DR^{âˆ’/low} myeloidâ€derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. <i>Hepatology Research</i> , 2017, 47, 1061-1071.	1.8	56
29	Overexpression of galectinâ€1 is associated with poor prognosis in human hepatocellular carcinoma following resection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1312-1319.	1.4	52
30	CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5â€LSD1â€NFâ€B oncogenic signaling. <i>Clinical and Translational Medicine</i> , 2020, 10, e233.	1.7	51
31	Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence. <i>Journal of Hepatology</i> , 2019, 71, 1152-1163.	1.8	49
32	Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma. <i>Clinica Chimica Acta</i> , 2016, 462, 15-22.	0.5	47
33	Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection. <i>Oncotarget</i> , 2016, 7, 70654-70668.	0.8	44
34	Prognostic Significance of Capn4 Overexpression in Intrahepatic Cholangiocarcinoma. <i>PLoS ONE</i> , 2013, 8, e54619.	1.1	43
35	Establishment of a hepatocellular carcinoma patientâ€derived xenograft platform and its application in biomarker identification. <i>International Journal of Cancer</i> , 2020, 146, 1606-1617.	2.3	32
36	Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. <i>Liver International</i> , 2021, 41, 562-573.	1.9	32

#	ARTICLE	IF	CITATIONS
37	BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways. <i>Cell Death and Disease</i> , 2018, 9, 1036.	2.7	31
38	HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 47121-47135.	0.8	29
39	Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 157-167.	0.6	27
40	KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. <i>Journal of Cancer</i> , 2019, 10, 3914-3925.	1.2	27
41	Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF- κ B signaling pathways synergistically. <i>Clinical and Translational Medicine</i> , 2021, 11, e335.	1.7	27
42	Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 1686-1694.	0.7	25
43	Circulating tumor cells are an indicator for the administration of adjuvant transarterial chemoembolization in hepatocellular carcinoma: A single-center, retrospective, propensity-matched study. <i>Clinical and Translational Medicine</i> , 2020, 10, e137.	1.7	25
44	An SCD1-dependent mechanoresponsive pathway promotes HCC invasion and metastasis through lipid metabolic reprogramming. <i>Molecular Therapy</i> , 2022, 30, 2554-2567.	3.7	24
45	Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma. <i>EBioMedicine</i> , 2020, 62, 103107.	2.7	23
46	Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma. <i>Cancer Letters</i> , 2015, 366, 112-122.	3.2	21
47	PDXliver: a database of liver cancer patient derived xenograft mouse models. <i>BMC Cancer</i> , 2018, 18, 550.	1.1	20
48	Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection. <i>Cancer Cytopathology</i> , 2020, 128, 733-745.	1.4	19
49	Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score-matched survival analysis. <i>Cancer Medicine</i> , 2019, 8, 6933-6944.	1.3	14
50	High level of serum protein DKK1 predicts poor prognosis for patients with hepatocellular carcinoma after hepatectomy. <i>Hepatic Oncology</i> , 2015, 2, 231-244.	4.2	13
51	Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 15, 8396-8404.	0.8	13
52	CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis. <i>Clinical and Translational Medicine</i> , 2022, 12, e794.	1.7	13
53	A new use for an old index: preoperative high-density lipoprotein predicts recurrence in patients with hepatocellular carcinoma after curative resections. <i>Lipids in Health and Disease</i> , 2017, 16, 123.	1.2	11
54	Serum IgG4:IgG Ratio Predicts Recurrence of Patients with Hepatocellular Carcinoma after Curative Resection. <i>Journal of Cancer</i> , 2017, 8, 1338-1346.	1.2	11

#	ARTICLE	IF	CITATIONS
55	BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity. <i>Cell Death and Disease</i> , 2020, 11, 895.	2.7	11
56	High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24259.	0.9	10
57	Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis. <i>Oncologist</i> , 2019, 24, 997-1007.	1.9	9
58	Circulating tumor cell detection and single-cell analysis using an integrated workflow based on Chimerax [®] 120 Platform: A prospective study. <i>Molecular Oncology</i> , 2021, 15, 2345-2362.	2.1	9
59	Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization. <i>Clinica Chimica Acta</i> , 2020, 511, 67-74.	0.5	8
60	Mucin 1 promotes tumor progression through activating WNT/ β -catenin signaling pathway in intrahepatic cholangiocarcinoma. <i>Journal of Cancer</i> , 2021, 12, 6937-6947.	1.2	8
61	Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 24.	7.1	7
62	Prognostic value of fever grade combined with neutrophil percentage in hepatocellular carcinoma patients presenting fever as the initial manifestation. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6281-6290.	1.0	5
63	Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. <i>Frontiers in Oncology</i> , 2021, 11, 704042.	1.3	5
64	Plasma MicroRNA Panel Predicts Early Tumor Recurrence in Patients with Hepatocellular Carcinoma after Liver Transplantation. <i>Journal of Cancer</i> , 2021, 12, 7190-7200.	1.2	5
65	Low expression is associated with poor prognosis in patients with hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2017, 7, 2465-2477.	1.4	5
66	Hsa_circ_0003945 promotes progression of hepatocellular carcinoma by mediating miR-34c-5p/LGR4/ β -catenin axis activity. <i>Journal of Cellular and Molecular Medicine</i> , 2022, , .	1.6	4
67	Limited bias effect of intratumoral heterogeneity on genetic profiling of hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 112-120.	0.6	2
68	ASO Author Reflections: Annexin A3 as a Potential Biomarker for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 529-530.	0.7	1
69	Dickkopf-1 and hepatocellular carcinoma – Authors' reply. <i>Lancet Oncology</i> , The, 2012, 13, e410-e411.	5.1	0